1.
Jenson AB, Kurman RJ, Lancaster Wo. Human papillomaviruses.
In: Belshe RB, editor. Textbook of Human Virology. Littleton,MA:
PSG-Wright; 1984. p 951-68.
2.
Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. The
causal relation between human papillomavirus and cervical
cancer. J Clin Pathol2002 Apr;55(4):244-65.
3.
Gaarenstroom KN, Melkert P, Walboomers JMM, van den Brule
AJC, van Bommel PFJ, Meijer CJLM, Vorhorst FJ, Kenemans
P, Helmerhorst ThJM. Human papillomavirus ONA and genotypes:
prognostic factors for progression of cervical intraepithelial
neoplasia. Int J Gynecol Cancer 1994;4:73-8.
4.
Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos
M, Miyamura RA, Ouarte-Franco E, Rohan TE, Ferenczy A,
Villa LL, Franco EL. Persistent human papillomavirus
infection as a predictor of cervical intraepithelial neoplasia.
JAMA 2001 Oec;286(24):31 06-14.
5.
Nobbenhuis MAE, Walboomers JMM, Helmerhorst T JM, Rozendaal
L, Remmink AJ, Risse EKJ, van der Linden HC, Voorhorst
FJ, Kenemans P, Meijer CJLM. Relation of human papillomavirus
status to cervicallesions and consequences for cervical-cancer
screening: a prospective study. Lancet 1999 Jul;354(1):20-5.
6.
CasUe PE, Wacholder S, Sherman ME, Lorincz AT, Glass AG,
Scott OR, Rush BB, Oemuth F, Schiffman M. Absolute
risk of a subsequent abnormal Pap among oncogenic human
papillomavirus ONA-positive, cytologically negative women.
Cancer 2002 Nov;95(10):2145-51.
7.
Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson
M, Morales J, Balmaceda I, Greenberg MO, Alfaro M, Burk
RO, Wacholder S, Plummer M, Schiffman M. Population-based
study of human papillomavirus infection and cervical neoplasia
in rural Costa Rica. J NaU Cancer Inst 2000 Mar;92(6):464-74.
8.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague
X, Shah KV, Snijders PJF, Meijer CJLM, for the Intemational
Agency for Research on Cancer Multicenter Cervical Cancer
Study Group. Epidemiologic classification of human
papillomavirus types associated with cervical cancer.
N Engl J Med 2003 Feb;348(6):518- 27.
9.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague
X, Shah KV, Meheus A. The Epidemiology of Human Papillomavirus
and Cervical Cancer. Lyon: International Agency for
Research on Cancer; 1992.
10.
Remmink AJ, Walboomers JMM, Helmerhorst T JM, Voorhorst
FJ, Rozendall L, Risse EKJ, Meijer CJLM, Kenemans P. The
presence of persistent high-risk HPV genotypes in dysplastic
cervicallesions is associated with progressive disease:
natural history up to 36 months. Int J Cancer 1995;61
:306-11.
11.
Lorincz A T, Quinn AP, Lancaster WO, Temple GF. A new
type of papillomavirus associated with cancer of the uterine
cervix. Virology 1987;159:187-90.
12.
Meyer T, Amdt R, Christophers E, Beckmann E-R, Schroder
S, Gissmann L, Stockfleth E. Association of rare human
papillomavirus types with genital premalignant and malignant
lesions. J Infect Ois 1998 Jul;178(1):252-5.
13.
Lorincz A T, Reid R, Jenson AB, Greenberg MO, Lancaster
W, Kurman RJ. Human papillomavirus infection of the
cervix: relative risk associations of 15 common anogenital
types. Obstet Gynecol1992 Mar;79(3):328-37.
14.
Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peta
J, Schiffman MH, Moreno V, Kurman R, Shah KV, International
Biologic Study on Cervical Cancer (IBSCC) Study Group.
Prevalence of human papillomavirus in cervical cancer:
a worldwide perspective. J NaU Cancer Inst 1995 Jun;87(11
):796-802.
15.
Shimoda K, Lorincz AT, Temple GF, Lancaster WO. Human
papillomavirus type 52: a new virus associated with cervical
neoplasia. J Gen ViroI1988;69:2925-8.
16.
Volpers C, Streeck RE. Genome organization and nucleotide
sequence of human papillomavirus type 39. Virology
1991 Mar;181(1):419-23.
17.
Matsukura T, Sugase M. Molecular cloning ora novel
human papillomavirus (type 58) from an invasive cervical
carcinoma. Virology 1990 Aug;177(2):833-6.
18.
Rho J, Roy-Burman A, Kim H, de Villiers E-M, Matsukura
T, Choe J. Nucleotide sequence and phylogenetic classification
of human papillomavirus type 59. Virology 1994;203:158-61.
19.
Longuet M, Beaudenon S, Orth G. Two novel genital human
papillomavirus (HPV) types, HPV68 and HPV70, related to
lhe potentially oncogenic HPV39. J Clin Microbiol1996
Mar;34(3):738-44.
20.
Stewart A-CM, Gravitt PE, Cheng S, Wheeler CM. Generation
of entire human papillomavirus genomes by long PCR: frequency
of errors produced during amplification. Genome Res
1995;5(1 ):79-88.
21.
Schiffman MH. Latest HPV findings: some clinical implications.
Contemporary OB/GYN 1993 Oct:27-41.
22.
Stellato G, Nieminen P, Aho H, Vesterinen E, Vaheri A,
Paavonen J. Human papillomavirus infection ofthe female
genital tract: correlation of HPV DNA with cytologic,
colposcopic, and natural history findings. Eur J Gynaec
Oncol 1992;13(3):262-7.
23.
Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen
J, Beckmann AM, DeRouen TA, Galloway DA, Vemon D, Kiviat
NB. A cohort study of lhe risk of cervical intraepithelial
neoplasia grade 2 or 3 in relation to papillomavirus infection.
N Engl J Med 1992 Oct;327(18):1272-8.
24.
Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD.
Natural history of cervicovaginal papillomavirus infection
in young women. N Engl J Med 1998 Feb;338(7):423-8.
25.
Sherman ME, Lorincz A T, Scott DR, Wacholder S, Castle
PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman
M. Baseline cytology, human papillomavirus testing,
and risk for cervical neoplasia: a 1 O-year cohort analysis.
J Natl Cancer Inst 2003 Jan;95(1 ):46-52.
26.
Ylitalo N, Josefsson A, Melbye M, Sorensen P, Frisch M,
Andersen PK, Spal~n P, Gustafsson M, Magnusson P, Ponten
J, Gyllensten U, Adami H-O. A prospective study showing
long-term infection with human papillomavirus 16 before
lhe development of cervical carcinoma in situo Cancer
Res 2000 Nov;60(21 ):6027-32.
27.
Wallin K-L, Wiklund F, Angstrom T, Bergman F, Stendahl
U, Wadell G, Hallmans G, Dillner J. Type-specific persistence
of human papillomavirus DNA before lhe development of
invasive cervical cancer. N Engl J Med 1999 Nov;341
(22): 1633-8.
28.
van der Graaf Y, Molijn A, Doomewaard H, Quint W, van
Doorn L-J, van den Tweel J. Human papillomavirus and
lhe long-term risk of cervical neoplasia. Am J Epidemiol2002
Jul;156(2):158-64.
29.
Petry KU, Bohmer G, Iftner T, Davies P, Brummer O, Kuhnle
H. Factors associated with an increased risk of prevalent
and incident grade II1 cervical intraepithelial noeplasia
and invasive cervical cancer among women with Papanicolaou
tests classified as grades I or I1 cervical intraepithelial
neoplasia. Am J Obstet Gynecol2002 Jan;186(1 ):28-34.
30.
Hopman EH, Rozendaal L, Voorhorst FJ, Walboomers JMM,
Kenemans P, Helmerhorst ThJM. High risk human papillomavirus
in women with normal cervical cytology prior to lhe development
of abnormal cytology and colposcopy. Br J Obstet Gynaecol
2000 May; 107:600-4.
31.
Woodman CBJ, Collins S, Winter H, Bailey A, Ellis J, Prior
P, Yates M, Rollason TP. Natural history of cervical
human papillomavirus infection in young women: a longitudinal
cohort study. Lancet 2001 Jun;357(9271): 1831-6.
32.
Zielinski GD, Snijders PJF, Rozendaal L, Voorhorst FJ,
Runsink AP, de Schipper FA, Meijer CJLM. High-risk
HPV testing in women with borderline and mild dyskaryosis:
long-term follow-up data and clinical relevance. J
Pathol 20010ct;195(3):300-6.
33.
Rozendaal L, Walboomers JMM, van der Linden JC, Voorhorst
FJ, Kenemans P, Helmerhorst ThJM, van Ballegooijen M,
Meijer CJLM. PCR-based high-risk HPV test in cervical
cancer screening gives objective risk assessment of women
with cytomorphologically normal cervical smears. Int
J Cancer 1996 Dec;68(6):766-9.
34.
Centers for Disease Controlo Recommendations for prevention
of HIV transmission in health-care settings. MMWR
1987 Aug;36(suppl. 2S):3S-17S.
35.
Sehulster LM, Hollinger FB, Dreesman GR, Melnick JL.
Immunological and biophysical alteration of hepatitis
B virus antigens by sodium hypochlorite disinfection.
Appl Environ Microbiol1981 Nov;42(5):762-7.
36.
National Committee for Clinical Laboratory Standards.
Statistical quality contrai for quantitative measurements:
principies and definitions; approved guideline-second
edition. 2nd ed. Wayne,PA: NCCLS; 1999.
37.
Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz
JA, Landesman SH. Declining prevalence of cervicovaginal
human papillomavirus infection with age is independent
of other risk factors. Sex Transm Dis 1996;23(4 ):333-41.
38.
Pfister, H.; Hettich, I.; Runne, U.; Gissmann, L.; Chilf,
G. N. Characterization of human papillomavirus type
13 from focal epithelial hyperplasia Heck lesions.
J Virol 47:363-366; 1983.
39.
Kahn, T.; Schwarz, E.; zur Hausen, H. Molecular cloning
and characterization of the DNA of a new human papillomavirus
(HPV 30) from a laryngeal carcinoma. Int J Cancer
51 :61-65; 1986.
40.
Vernon SD, Unger ER, Williams D. Comparison of human
papillomavirus detection and typing by cycle sequencing,
line blotting, and Hybrid Capture. J Clin Microbiol2000
Feb;38(2):651-5.
41.
Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim
A, Herrero R, Bratti MC, Sherman ME, Lorincz A. Restricted
cross-reactivity of Hybrid Capture 2 with non-oncogenic
human papillomavirus types. Cancer Epidemiol Biomarkers
Prev 2002 Nov;11 :1394-9.
42.
Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau M-C,
Desy M, Rohan TE. Epidemiology ofacquisition and clearance
of cervical human papillomavirus infection in women from
a high-risk area for cervical cancer. J Infect Dis
1999 Nov;180(5):1415-23.
43.
Liaw K-L, Glass AG, Manos MM, Greer CE, Scott DR, Sherman
M, Burk RD, Kurman RJ, Wacholder S, Rush BB, Cadell DM,
Lawler P, Tabor D, Schiffman M. Detection of human
papillomavirus DNA in cytologically normal women and subsequent
cervical squamous iro(raepitheliallesions. J Natl
Cancer Inst 1999 Jun;91 (11 ):954-60.
44.
Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti
M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg
MD, Lorincz AT. HPV DNA testing in cervical cancer
screening: results from women in a high-risk province
of Costa Rica. JAMA 2000 Jan;283(1 ):87-93.
45.
Wright TC, Jr., Denny L, Kuhn L, Pollack A, Lorincz A.
HPV DNA testing of self-collected vaginal samples compared
with cytologic screening to detect cervical cancer. JAMA
2000 Jan;283(1):81-6.
46.
Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li
L, Pan QJ, Fischer C, Lorincz A, Zahniser D. Shanxi. Province
cervical cancer screening study: a cross-sectional comparative
trial of multiple techniques to detect cervical neoplasia.
Gynecol ancol 2001 Nov;83(2):439-44.
47.
Bory J-P, Cucherousset J, Lorenzato M, Gabriel R, Quereux
C, Birembaut P, Clavel C. Recurrent human papillomavirus
infection detected with the hybrid capture 1I assay selects
women with normal cervical smears at risk for developing
high grade cervicallesions: a longitudinal study of 3,091
women. Int J Cancer 2002 Dec;102(5):519-25.
48.
Petry K-U, Menton S, Menton M, van Loenen-Frosch F, de
Carvalho Gomes H, Holz B, Schopp B, Garbrecht- Buettner
S, Davies P, Boehmer G, van den Akker E, Iftner T. Inclusion
of HPV testing in routine cervical cancer screening for
women above 29 years in Germany: results for 8468 patients.
Br J Cancer 2003 May;88(10):1570-7.
--------------------------------------------------------------
